Anthropic before OpenAI: The IPO race that turned into an AI policy fight
The two labs that defined the generative-AI era are no longer competing on benchmarks — they are competing for the legitimacy that only public markets and political coalitions can grant.
On 26 June 2026, the prediction market Polymarket priced a 77% probability that Anthropic would list on a public exchange before OpenAI — a striking inversion for two labs that, eighteen months earlier, were still being discussed primarily as research shops. That same afternoon, OpenAI was reported to be weighing a 2027 IPO that would follow an expected Anthropic debut, while SoftBank's shares fell roughly 12% on concerns that any further delay would erode the carrying value of its OpenAI stake. What had been framed as a horse race between two research labs has, in the span of a quarter, become something more uncomfortable: a stress test for how the frontier-AI industry intends to govern itself.
The IPO question is no longer about capital. Both Anthropic and OpenAI have, by any reasonable measure, already raised more private capital than they can productively deploy. The IPO question is about political standing — about which lab gets to write the rules the other one will have to live under.
From benchmarks to ballots
For most of 2024 and 2025, the public contest between the two labs was framed in technical terms: which one shipped better reasoning models, which one retained more enterprise customers, which one earned the more flattering safety-audit headlines. That framing is now obsolete. As a TechCrunch analysis published on 26 June argued, AI models have progressed to a point where their capabilities carry real political consequences, and responding to those consequences will require collective action rather than laboratory-by-laboratory posturing. The shift is visible everywhere: in the White House's voluntary safety commitments, in the EU AI Act's tiered obligations, and in state-level procurement fights over which vendors public universities and pension funds are permitted to deploy.
A public listing changes the calculus on every one of those fronts. A company with public-market disclosure obligations, a passive index shareholder base, and quarterly earnings calls has different leverage over its own safety commitments than a private firm whose only outside counterweight is a handful of venture capitalists and an internal "Responsible Scaling Policy." The labs that list first get to define the disclosure template the others will be measured against — and that template is, in practice, a regulatory artefact.
The SoftBank signal
The clearest read on the financial stakes came not from either lab but from Tokyo. SoftBank's roughly 12% share-price move on 26 June, attributed by market coverage to OpenAI IPO-delay concerns, is a useful proxy for how exposed the wider listed-equity complex has become to the timing of a single private listing. SoftBank's reported OpenAI exposure is large enough that even a six-to-twelve-month slip in the listing window now moves the parent's market capitalisation by double digits in a single session.
That exposure is doing two things at once. It is accelerating the pressure on OpenAI to demonstrate a credible path to public markets, and it is concentrating the lobbying bandwidth around the actual listing — over which exchange, under which disclosure regime, with which carve-outs for safety-related R&D that the company would prefer not to itemise. The OpenAI IPO is being framed, in investment-bank pitch decks and in SoftBank's investor communications alike, as a 2027 event. Anthropic's expected debut, by contrast, is being priced in 2026 by prediction markets.
What a public Anthropic actually changes
The more interesting structural question is what happens to AI safety governance if Anthropic reaches the public market first. Anthropic has built its commercial identity around a comparatively public set of safety commitments — its Responsible Scaling Policy, its model spec, its public evaluations — and a public listing would force those commitments into the regulatory perimeter in a way that an S-1 filing makes durable. Competitors, including OpenAI, would then face a choice: match the disclosure floor and accept the cost, or accept the political cost of being visibly less transparent.
There is a counter-read. The same disclosure floor that legitimises Anthropic's safety posture also gives its commercial critics more ammunition: specific capability thresholds, specific revenue concentration, specific compute commitments that can be quoted back at the company in congressional hearings and antitrust filings. A safety-led lab under public-market discipline is not obviously more virtuous than a safety-led lab under venture-capital discipline — it is differently constrained, with quarterly earnings replacing funding rounds as the binding clock.
The OpenAI camp has a structurally different position. Its product surface is broader, its enterprise footprint is larger, and its political relationships in Washington, Brussels, and Tokyo are arguably deeper. A 2027 IPO, properly staged, allows it to set a different template — one closer to a consumer-internet listing than to a frontier-lab listing — and to argue, plausibly, that its governance constraints already exceed anything a public-disclosure regime would impose.
The political horizon
Both labs are now operating in a regime where the most consequential decisions about their future are being made outside their headquarters. The U.S.–China export-control schedule, the EU AI Act's general-purpose-model obligations, and the procurement rules of sovereign wealth funds from Riyadh to Singapore are all converging on a single question: what does a frontier lab have to publish about itself before it can sell to a government? The IPO race, on this reading, is not about which lab gets richer. It is about which lab gets to define the disclosure vocabulary the others will be forced to adopt.
That is the point the Polymarket contract is, perhaps inadvertently, capturing. A 77% implied probability is not a forecast about engineering talent or product roadmap. It is a forecast about who blinks first in a regulatory negotiation that neither lab can win alone.
What remains genuinely uncertain
The honest ledger on this story is short. The thread sources do not specify the targeted listing exchange for either company, the precise size or structure of either offering, or the regulatory carve-outs either lab intends to negotiate. SoftBank's 12% move is reported as a single-day price reaction and not, in the materials available to this publication, as a confirmed causal attribution to OpenAI timing — the broader market, yen volatility, and unrelated portfolio disclosures could all be in the mix. The Polymarket 77% figure is a trader's estimate, not a corporate announcement. The TechCrunch framing of "collective action" is an argument, not a policy.
What can be said with confidence is narrower. Two frontier labs are now publicly tracked as imminent public-market candidates. One of their largest private backers has already taken a double-digit hit on listing-timing concerns. The political conversation about AI governance has shifted, in the past quarter, from hypothetical to operational. And the order in which those two events resolve is now itself a market-moving variable.
Desk note: Monexus treats this as a governance story that happens to involve IPO paperwork, not an IPO story that happens to involve governance. The wire coverage on 26 June led with the listing question; the structural question — who gets to set the disclosure floor — is what will define the next twelve months.
Wire provenance
This editorial synthesis draws on the following public wire/social posts:
- https://t.me/CryptoBriefing/0
- https://t.me/CryptoBriefing/0
- https://x.com/polymarket/status/0